ISSN:
1573-7241
Keywords:
bucindolol
;
ventricular fibrillation
;
myocardial ischemia
;
myocardial blood flow
;
beta antagonists
Source:
Springer Online Journal Archives 1860-2000
Topics:
Medicine
Notes:
Summary Bucindolol is a new beta blocker with marked vasodilatory properties and intrinsic sympathomimetic activity. We tested its potential effect against ventricular fibrillation (VF), in a pig model of acute myocardial ischemia. Bucindolol 6 mg/kg IV was administered in two equally divided doses, the first 30 minutes prior to, and the second 10 minutes after, ligation of the anterior descending coronary artery (CAL) in anesthetized open-chest pigs. Bucindolol decreased the incidence of VF to 1/11 versus 14/16 in the control group (p〈0.005). Bucindolol also decreased the duration of ventricular tachycardia, 15±8 seconds versus 104±32 seconds in the control group (p〈0.01). Bucindolol maintained LVmaxdP/dt at predrug and pre-CAL values, whereas LVmaxdP/dt was decreased by CAL in the control group. Bucindolol decreased arterial pressure and heart rate. Bucindolol increased blood flow in the peripheral ischemic zone (24.6±1.8% versus 16.2±1.7% (percent of pre-CAL value) in controls, p〈0.002), as well as in the nonischemic zones (perlischemic zone: 126.4±6.1% versus 96.7±4.8% in the control group, p〈0.0005; remote nonischemic zone: 126.6± 7.1% versus 87.1±4.3% of pre-CAL value in the control group, p〈0.0001). Bucindolol had marked antiarrhythmic effects that were associated with beneficial effects on the mechanical function of the left ventricle and on blood flow to the ischemic myocardium.
Type of Medium:
Electronic Resource
URL:
http://dx.doi.org/10.1007/BF00051144
Permalink
